TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03813771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benepali
Description: Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Sulfasalazine
Description: Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
Study: NCT01720212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral
Study: NCT03163810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia Verju Laser
Description: The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia EVRL Laser
Description: The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
Study: NCT04002479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT02223182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Milk 150 mcg
Description: Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Milk 300 mcg
Description: Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Milk 500 mcg
Description: Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Viaskin Placebo
Description: Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
Study: NCT03663712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells
Study: NCT00924989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Administered orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally
Study: NCT02930876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
Study: NCT00252629

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nasal CPAP treatment during sleep
Description: After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP treatment during sleep
Description: After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
Study: NCT00745173

Intervention type: DRUG
Group type: OTHER
Intervention: Premarin
Study: NCT04069078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule
Description: Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia
Study: NCT02717845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ellipse
Description: diagnostic CT scan imaging

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tomofix
Description: diagnostic CT scan imaging
Study: NCT00684580

Intervention type: OTHER
Intervention: Data Collection
Description: Continuing review of outcomes and late toxicities
Study: NCT03606395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NV-5138
Description: single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NV-5138
Description: single ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo liquid solution to mimic NV-5138
Study: NCT03606395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo liquid solution to mimic NV-5138
Study: NCT01936727

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Study: NCT01184131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentor Training
Description: Four 2 hour sessions of Mentor Training
Study: NCT03750695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: 40 minutes of quiet rest in semi-recumbent position
Study: NCT04245371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1.8%
Description: Topical Patch
Study: NCT04129554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 injection will be administered subcutaneously once every 4 weeks up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for JNJ-73763989
Description: Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for JNJ-56136379
Description: Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) monohydrate
Description: ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir (ETV) monohydrate
Description: ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: TDF will be administered orally once daily up to 48 weeks as NA treatment.
Study: NCT04245371

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Patch
Study: NCT04129554

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: TDF will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: TAF will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir alafenamide (TAF)
Description: TAF will be administered orally once daily up to 48 weeks as NA treatment.
Study: NCT03711357

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 980 nm diode laser
Description: 980 nm high power diode laser device.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the diode laser fiber optic tip will be inserted in root canals, but will not be activated.
Study: NCT02179151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-440 for Injectable Suspension
Description: Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-440 for Injectable Suspension
Description: Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
Study: NCT03069469

Intervention type: DRUG
Group type: OTHER
Intervention: Vimseltinib
Description: Colony-stimulating factor 1 receptor (CSF1R) inhibitor
Study: NCT02179151

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-440 Placebo for Injectable Suspension
Description: Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
Study: NCT01861249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR339658
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous
Study: NCT03201276

Intervention type: DRUG
Intervention: Glucosamine Sulfate
Description: Patients taking glucosamine sulfate 1500mg every day for at least four days.
Study: NCT02972723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral Metformin 1g bd. (total = 2g per day) for 14 days
Study: NCT00775359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg tablets
Study: NCT02473055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Care
Description: skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
Study: NCT02024438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monosialotetrahexosylganglioside Sodium
Description: it is extracted from pig's brain,shenjie is the brand name

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Description: saline of the same appearance as monosialotetrahexosylganglioside Sodium
Study: NCT02929251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
Study: NCT03767595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProACT Adjustable Continence Therapy for Men
Description: The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.
Study: NCT03724175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodiol (ursodeoxycholic acid, UDCA)
Description: ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks for UC pouchitis patients
Study: NCT02691065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrase Inhibitor
Description: Raltegravir
Study: NCT04506619

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT00695110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) (300 mg T equivalents/dose)
Description: Three capsules each containing 100 mg testosterone (T) as TU, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose)
Description: Two capsules each containing 100 mg T as TU and 100 mg T as TE, BID. 400 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days. A 7-14 day washout period occurred between successive Treatment Periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)
Description: Two capsules each containing 100 mg T as TU, BID for 8 days. 200 mg T equivalents BID 30 minutes after initiation of meals (breakfast and dinner), except for Day 8 when the morning dose was administered fasting. A 7-14 day washout period occurred between successive Treatment Periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
Description: Two capsules each containing 150 mg T as TU and 150 mg T as TE, BID. 300 mg T equivalents BID 30 minutes after initiation of breakfast and dinner meals for 7 days.
Study: NCT03486197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo neutron radiation therapy
Study: NCT03628924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab dose 1
Description: Participants will receive guselkumab dose 1 IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab dose 2
Description: Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab dose 2
Description: Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab dose 2
Description: Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab dose 3
Description: Participants will receive guselkumab dose 3 SC in Group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
Study: NCT06330831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive, Group Based Constraint Induced Therapy (CIMT)
Description: See arm description. Children who were in study 2 received two consecutive episodes of the intensive, group based CIMT intervention (episode 1 during the first summer, episode 2 during the following summer).
Study: NCT01515358

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3000328
Description: Administered orally
Study: NCT01258387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glial growth factor 2/ Neuregulin 1β3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04890756

Intervention type: OTHER
Intervention: observational
Description: The reliability was determined (n=100) by filling out the mBQ, two times, one week apart (test-retest).~For validation (n=45), the scores between the modified Baecke Questionnaire and the International Physical Activity Questionnaire were compared and the correlation between the modified Baecke Questionnaire and VO2max(via Astrand-Rhyming Cycle Ergometer Test) and between mBQ and interview (via METS) were assessed.

Intervention type: OTHER
Intervention: observational
Description: The reliability was determined (n=100) by filling out the mBQ, two times, one week apart (test-retest).~For validation (n=45), the scores between the modified Baecke Questionnaire and the International Physical Activity Questionnaire were compared and the correlation between the modified Baecke Questionnaire and VO2max(via Astrand-Rhyming Cycle Ergometer Test) and between mBQ and interview (via METS) were assessed.
Study: NCT02900027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APOC-III-L-Rx
Description: Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
Study: NCT02641210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Treatment
Description: Periodontal Treatment using Gracey curettes and ultrasonic device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: All participants took Albendazole 400 mg before the intervention.
Study: NCT01577732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV+Hib™
Description: Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.
Study: NCT03082885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin-α1
Description: 1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.
Study: NCT01102296

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: 2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: 2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: 2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.
Study: NCT01692262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of AZD5363
Description: Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of AZD5363
Description: Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent dosing of AZD5363
Description: Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.
Study: NCT03724474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be SMART
Description: The behavioral intervention will examine 12-week changes in sleep metrics and physical activity, compared to baseline measures, between subjects randomly assigned to a treatment (Be SMART) and an active control (Fitbit Only) condition (n=30, respectively).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Be SMART
Description: The behavioral intervention will examine 12-week changes in sleep metrics and physical activity, compared to baseline measures, between subjects randomly assigned to a treatment (Be SMART) and an active control (Fitbit Only) condition (n=30, respectively).
Study: NCT03313089

Intervention type: BEHAVIORAL
Intervention: Papas más nutritivas (PSAN)
Description: Activities of the project Papas más nutritivas